Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,currency,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,INNMF,2402000.0,124821000,730819,,-884893,,-884893,317032,183967,-885361,-885361,,-172,,,,0,337036,1222397,153068,468,,-884893,-884893,7938000.0,538000.0,10340000.0,10878000.0,136554000.0,87000.0,-125206000.0,-1008000.0,1848000.0,538000.0,-1008000.0,5000.0,2935000.0,1000000.0,538000.0,0,-2500,33442,38584,-958267,-694,-988514,400,-5142,-104020,-2500,2397000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.1308 - 0.1308,0.1308,0.0,0.0,0,0,finmb_25021935,Other OTC,Amplia Therapeutics Limited,AUD,5512,4371,0.0097999945,0.08099169,0.121 - 0.241,-0.1102,-0.45726144,0.121,0.241,-0.018,USD,4,0.096,0.14822857,-0.017428577,-0.117579065,0.17769565,-0.046895653,-0.26390997,17674742,1.3625,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.1308,1630439426,0.0,0.15,0.1308,0.1308,17400,AMPLIA THERAPEUTICS LTD,us_market,PRE,0.25,,,0.241,0.121,0.1482,0.1777,5.51k,4.37k,124.82M,,60.45M,30.26%,13.75%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",-148.70%,-152.54%,-14.63%,-24.08%,1.53M,0.02,"1,869.40%",1.22M,-2.34M,-2.28M,-0.0180,,1.85M,0.02,,,5.45,0.10,-2.92M,-2.24M,Value,3000,Healthcare,"Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",Melbourne,61 2 8003 3650,VIC,1609372800,Australia,http://www.ampliatx.com,86400,90 Collins Street,61 2 9225 5050,Biotechnology,Level 21
t-1,INNMF,2402000.0,124821000,730819,,-884893,,-884893,317032,183967,-885361,-885361,,-172,,,,0,337036,1222397,153068,468,,-884893,-884893,7938000.0,538000.0,10340000.0,10878000.0,136554000.0,87000.0,-125206000.0,-1008000.0,1848000.0,538000.0,-1008000.0,5000.0,2935000.0,1000000.0,538000.0,0,-2500,33442,38584,-958267,-694,-988514,400,-5142,-104020,-2500,2397000.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.1308 - 0.1308,0.1308,0.0,0.0,0,0,finmb_25021935,Other OTC,Amplia Therapeutics Limited,AUD,5512,4371,0.0097999945,0.08099169,0.121 - 0.241,-0.1102,-0.45726144,0.121,0.241,-0.018,USD,4,0.096,0.14822857,-0.017428577,-0.117579065,0.17769565,-0.046895653,-0.26390997,17674742,1.3625,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.1308,1630439426,0.0,0.15,0.1308,0.1308,17400,AMPLIA THERAPEUTICS LTD,us_market,PRE,0.25,,,0.241,0.121,0.1482,0.1777,5.51k,4.37k,124.82M,,60.45M,30.26%,13.75%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",-148.70%,-152.54%,-14.63%,-24.08%,1.53M,0.02,"1,869.40%",1.22M,-2.34M,-2.28M,-0.0180,,1.85M,0.02,,,5.45,0.10,-2.92M,-2.24M,Value,3000,Healthcare,"Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",Melbourne,61 2 8003 3650,VIC,1609372800,Australia,http://www.ampliatx.com,86400,90 Collins Street,61 2 9225 5050,Biotechnology,Level 21
t-2,INNMF,4062508.0,124821000,375181,,-255607,,-255607,250468,427033,-284639,-284639,,-172,,,,0,429964,714603,2932,29032,,-255607,-255607,7937932.0,615552.0,12000440.0,12615992.0,136487435.0,912815.0,-123437295.0,-1049700.0,3764648.0,615552.0,-1049700.0,597.0,4677463.0,,615552.0,0,-2500,1798058,1993916,1328267,-306,-469486,100,-195858,-213980,-2500,4061911.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.1308 - 0.1308,0.1308,0.0,0.0,0,0,finmb_25021935,Other OTC,Amplia Therapeutics Limited,AUD,5512,4371,0.0097999945,0.08099169,0.121 - 0.241,-0.1102,-0.45726144,0.121,0.241,-0.018,USD,4,0.096,0.14822857,-0.017428577,-0.117579065,0.17769565,-0.046895653,-0.26390997,17674742,1.3625,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.1308,1630439426,0.0,0.15,0.1308,0.1308,17400,AMPLIA THERAPEUTICS LTD,us_market,PRE,0.25,,,0.241,0.121,0.1482,0.1777,5.51k,4.37k,124.82M,,60.45M,30.26%,13.75%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",-148.70%,-152.54%,-14.63%,-24.08%,1.53M,0.02,"1,869.40%",1.22M,-2.34M,-2.28M,-0.0180,,1.85M,0.02,,,5.45,0.10,-2.92M,-2.24M,Value,3000,Healthcare,"Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",Melbourne,61 2 8003 3650,VIC,1609372800,Australia,http://www.ampliatx.com,86400,90 Collins Street,61 2 9225 5050,Biotechnology,Level 21
t-3,INNMF,4062508.0,124821000,375181,,-255607,,-255607,250468,427033,-284639,-284639,,-172,,,,0,429964,714603,2932,29032,,-255607,-255607,7937932.0,615552.0,12000440.0,12615992.0,136487435.0,912815.0,-123437295.0,-1049700.0,3764648.0,615552.0,-1049700.0,597.0,4677463.0,,615552.0,0,-2500,1798058,1993916,1328267,-306,-469486,100,-195858,-213980,-2500,4061911.0,en-US,US,EQUITY,False,Delayed Quote,0.0,0.1308 - 0.1308,0.1308,0.0,0.0,0,0,finmb_25021935,Other OTC,Amplia Therapeutics Limited,AUD,5512,4371,0.0097999945,0.08099169,0.121 - 0.241,-0.1102,-0.45726144,0.121,0.241,-0.018,USD,4,0.096,0.14822857,-0.017428577,-0.117579065,0.17769565,-0.046895653,-0.26390997,17674742,1.3625,15,America/New_York,EDT,-14400000,PNK,0,False,False,0.1308,1630439426,0.0,0.15,0.1308,0.1308,17400,AMPLIA THERAPEUTICS LTD,us_market,PRE,0.25,,,0.241,0.121,0.1482,0.1777,5.51k,4.37k,124.82M,,60.45M,30.26%,13.75%,,,,,,,,,,,0.00%,,,,,"Mar 30, 2021","Mar 30, 2021",-148.70%,-152.54%,-14.63%,-24.08%,1.53M,0.02,"1,869.40%",1.22M,-2.34M,-2.28M,-0.0180,,1.85M,0.02,,,5.45,0.10,-2.92M,-2.24M,Value,3000,Healthcare,"Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",Melbourne,61 2 8003 3650,VIC,1609372800,Australia,http://www.ampliatx.com,86400,90 Collins Street,61 2 9225 5050,Biotechnology,Level 21
